Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Standard
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. / Madhavan, Dharanija; Zucknick, Manuela; Wallwiener, Markus; Cuk, Katarina; Modugno, Caroline; Scharpff, Martina; Schott, Sarah; Heil, Jörg; Turchinovich, Andrey; Yang, Rongxi; Benner, Axel; Riethdorf, Sabine; Trumpp, Andreas; Sohn, Christof; Pantel, Klaus; Schneeweiss, Andreas; Burwinkel, Barbara.
In: CLIN CANCER RES, Vol. 18, No. 21, 21, 2012, p. 5972-5982.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
AU - Madhavan, Dharanija
AU - Zucknick, Manuela
AU - Wallwiener, Markus
AU - Cuk, Katarina
AU - Modugno, Caroline
AU - Scharpff, Martina
AU - Schott, Sarah
AU - Heil, Jörg
AU - Turchinovich, Andrey
AU - Yang, Rongxi
AU - Benner, Axel
AU - Riethdorf, Sabine
AU - Trumpp, Andreas
AU - Sohn, Christof
AU - Pantel, Klaus
AU - Schneeweiss, Andreas
AU - Burwinkel, Barbara
PY - 2012
Y1 - 2012
N2 - The use of circulating tumor cells (CTC) as a prognostic marker in metastatic breast cancer (MBC) has been well established. However, their efficacy and accuracy are still under scrutiny mainly because of methods of their enrichment and identification. We hypothesized that circulating miRNAs can predict the CTC status of patients with MBC, and tested for the same. Furthermore, we aimed at establishing a panel of circulating miRNAs capable of differentiating MBC cases from healthy controls.
AB - The use of circulating tumor cells (CTC) as a prognostic marker in metastatic breast cancer (MBC) has been well established. However, their efficacy and accuracy are still under scrutiny mainly because of methods of their enrichment and identification. We hypothesized that circulating miRNAs can predict the CTC status of patients with MBC, and tested for the same. Furthermore, we aimed at establishing a panel of circulating miRNAs capable of differentiating MBC cases from healthy controls.
KW - Humans
KW - Female
KW - Reproducibility of Results
KW - Prognosis
KW - Cell Count
KW - Transcriptome
KW - MicroRNAs/blood/genetics
KW - Neoplastic Cells, Circulating/metabolism
KW - Breast Neoplasms/blood/genetics/mortality/pathology
KW - Tumor Markers, Biological/blood/genetics
KW - Humans
KW - Female
KW - Reproducibility of Results
KW - Prognosis
KW - Cell Count
KW - Transcriptome
KW - MicroRNAs/blood/genetics
KW - Neoplastic Cells, Circulating/metabolism
KW - Breast Neoplasms/blood/genetics/mortality/pathology
KW - Tumor Markers, Biological/blood/genetics
M3 - SCORING: Journal article
VL - 18
SP - 5972
EP - 5982
JO - CLIN CANCER RES
JF - CLIN CANCER RES
SN - 1078-0432
IS - 21
M1 - 21
ER -